Idexx Laboratories Inc (IDXX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Idexx Laboratories Inc (IDXX)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Key Insights
Critical company metrics and information
Share Price
$435.69Market Cap
$35.68 BillionTotal Outstanding Shares
81.89 Million SharesTotal Employees
11,000Dividend
No dividendIPO Date
June 21, 1991SIC Description
In Vitro & In Vivo Diagnostic SubstancesHomepage
https://www.idexx.com
Historical Stock Splits
If you bought 1 share of IDXX before November 27, 2007, you'd have 4 shares today.
Execution Date | Split Amount |
---|---|
June 16, 2015 | 2-for-1 |
November 27, 2007 | 2-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-197.65 Million |
Net Cash Flow From Operating Activities, Continuing | $916.83 Million |
Net Cash Flow, Continuing | $-27.96 Million |
Net Cash Flow | $-23.06 Million |
Net Cash Flow From Financing Activities | $-747.13 Million |
Net Cash Flow From Financing Activities, Continuing | $-747.13 Million |
Net Cash Flow From Operating Activities | $916.83 Million |
Net Cash Flow From Investing Activities, Continuing | $-197.65 Million |
Exchange Gains/Losses | $4.90 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Average Shares | $83.47 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Other Operating Expenses | $1.01 Billion |
Net Income/Loss | $866.24 Million |
Income/Loss From Continuing Operations Before Tax | $1.09 Billion |
Provision For Loan, Lease, And Other Losses | $5.17 Million |
Operating Income/Loss | $1.11 Billion |
Benefits Costs and Expenses | $2.75 Billion |
Revenues | $3.84 Billion |
Basic Earnings Per Share | $10.46 |
Income Tax Expense/Benefit | $226.87 Million |
Research and Development | $213.88 Million |
Gross Profit | $2.33 Billion |
Basic Average Shares | $82.68 Million |
Income/Loss From Continuing Operations After Tax | $866.24 Million |
Net Income/Loss Available To Common Stockholders, Basic | $866.24 Million |
Income Tax Expense/Benefit, Deferred | $-62.43 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $2.75 Billion |
Diluted Earnings Per Share | $10.36 |
Cost Of Revenue | $1.51 Billion |
Operating Expenses | $1.22 Billion |
Net Income/Loss Attributable To Parent | $866.24 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Fixed Assets | $717.75 Million |
Other Current Liabilities | $739.64 Million |
Liabilities And Equity | $3.35 Billion |
Noncurrent Assets | $1.92 Billion |
Other Current Assets | $986.72 Million |
Liabilities | $1.73 Billion |
Prepaid Expenses | $57.22 Million |
Intangible Assets | $106.89 Million |
Other Non-current Assets | $1.09 Billion |
Accounts Payable | $110.60 Million |
Wages | $158.99 Million |
Noncurrent Liabilities | $723.49 Million |
Equity | $1.62 Billion |
Inventory | $389.80 Million |
Current Liabilities | $1.01 Billion |
Current Assets | $1.43 Billion |
Assets | $3.35 Billion |
Equity Attributable To Parent | $1.62 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Idexx Laboratories Inc (IDXX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.